Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngene InternationalBOM:539268 +0.86%81 EBITDA Margin % is 13.94% as of Jun. 2026, which is 59% below its 10-year median of 34.09. GuruFocus rates BOM:539268 with a GF Score™ of 81/100 and a GF Value™ of ₹727.64 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Syngene International ranks better than 77.83% on this metric.
Syngene International (BOM:539268) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Syngene International EBITDA Margin % Related Terms
Syngene International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Syngene International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539268 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Syngene International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Syngene International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngene International (BOM:539268) has a EBITDA Margin % of 13.94% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syngene International and its competitors. This is 59% below median its historical median of 34.09. Over the past decade, Syngene International's EBITDA Margin % has ranged from 21.97 to 41.01. According to the industry distribution chart, Syngene International ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 22.2%.
Is Syngene International's EBITDA Margin % too high?
Syngene International's current EBITDA Margin % of 13.94% is 59% below median its 10-year median of 34.09. Over the past 10 years, this metric has ranged from a low of 21.97 to a high of 41.01. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Syngene International's value of 13.94% is 178.8% above this industry median. Based on the distribution chart, Syngene International ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Syngene International has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #45 out of 203 companies for EBITDA Margin %. This places Syngene International in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Syngene International's value of 13.94% is 178.8% above this benchmark. Historically, Syngene International's own EBITDA Margin % has ranged from 21.97 to 41.01 over the past decade. While the company's 10-year median is 34.09 vs. the industry median of 5.00, Syngene International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngene International's current EBITDA Margin % of 13.94% is 178.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syngene International and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngene International's current EBITDA Margin % is 13.94%, which is 59% below median its own 10-year median of 34.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (BOM:539268) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹727.64, compared to a current price of ₹403.45 — trading 44.6% below its estimated fair value. The current EBITDA Margin % is 13.94%, which is 59% below median its 10-year median of 34.09 and 178.8% above the Medical Diagnostics & Research industry median of 5.00. Syngene International's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Syngene International (BOM:539268), the current EBITDA Margin % is 13.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (BOM:539268) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹403.45 is trading 44.6% below its estimated GF Value™ of ₹727.64.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for BOM:539268:
EBITDA Margin %: 13.94% (59% below median its 10-year median of 34.09)
GF Value™: ₹727.64 vs. price of ₹403.45 (44.6% below fair value)
Industry Position: 178.8% above the Medical Diagnostics & Research median (#45 of 203)
No single metric tells the full story. See the BOM:539268 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
81GF Score
Get the complete analysis for BOM:539268
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539268 has been successfully added to your 
